Webinar : The Ultimate Cleaning Validation Blueprint · Aug 27 · 10 AM EST. Save Your Seat
Webinar : The Ultimate Cleaning Validation Blueprint · Aug 27 · 10 AM EST Save Your Seat
Experience Leucine AI .
Powered Pharma Operations

Transform Your Pharma Operations with AI-Powered Intelligence. Experience how Leucine's integrated platform brings together manufacturing, quality, and laboratory operations in one digital ecosystem. Schedule a personalized demo to see how our AI solutions can optimize your processes, ensure compliance, and drive operational excellence.

See How AI Transforms Your Shop Floor Operations.
Experience firsthand how Leucine's 10x MES digitalizes batch records, streamlines production, and provides real-time monitoring of your manufacturing operations. Schedule a personalized demo to discover how our AI-powered platform can enhance your productivity while maintaining compliance.

Experience AI-Driven Quality Management in Action.
See how Leucine's 10x QMS automates compliance workflows, streamlines change control, and ensures regulatory adherence. Schedule a demo to learn how our AI-powered platform can help you manage quality processes more efficiently while reducing compliance risks.

Discover Smart Laboratory Operations Management.
Watch how Leucine's 10x LES orchestrates your lab operations, automates documentation, and ensures data integrity. Schedule a demo to see how our AI-powered platform can accelerate your testing processes while maintaining audit-readiness.

Optimize your manufacturing processes with paperless operations
Strengthen quality management and regulatory compliance
Accelerate laboratory operations and testing workflows

Connect with a Leucine Expert

Schedule a 30-Minute Product Demo with Expert Q&A

Sub System /
Material Storage and Control
Material Storage and Control
View Detailed Analysis

Analytics Overview

26
Form 483s Issued
5
483s converted to WL
28
Total Observation
Form 483s Issued
+74 from last period

Analytics Overview

Form 483 Conversion Rate by Year
Form 483s Issued (Yearly)

Recent Form 483s & Warning Letters

View all 483’s
Issue Date
Facility Name
Product Type
Form 483
Converted
Warning Letter
21 Feb 2025
Meds For Vets
Drugs
16 Jan 2025
Sanofi-Aventis Deutschland GmbH
Drugs
15 Nov 2024
Exela Pharma Sciences LLC
Drugs
06 Sep 2024
Annovex Pharma, Inc.
Drugs
27 Mar 2024
Alkem Laboratories Limited
Drugs

Top Investigators

Investigator Name
Form 483 Count
Warning Letter Count
Lauren R Brady
2
2
Logan Williams
2
0
Joan Cantellops
2
0
Jocelyn C Turner
2
2
Margaret M Annes
2
2
TITLE/ COMPANY Issue Date Status Details
Use of ingredients not intended for pharmaceutical use in sterile drug production
Meds For Vets
21 Feb 2025 Normal Justification: The observation highlights the use of non-pharmaceutical grade materials, indicating a failure in material control processes.
Excerpt: The (b) (4) for irrigation used is labeled "not for injection".
View Details
01 not are used for storage, and of all during DS manufacturing
Sanofi-Aventis Deutschland GmbH
16 Jan 2025 Normal Justification: The observation highlights inadequate storage affecting product quality, emphasizing the need for stringent material control during storage.
Excerpt: storage, and of all during DS manufacturing process. Although Step utilizes a less stringent generation process.
View Details
Separate or defined areas to prevent contamination or mix-ups are deficient regarding operations related to the holding of rejected components, drug product containers, and closures before disposition.
Exela Pharma Sciences LLC
15 Nov 2024 Normal Justification: Proper material storage controls prevent contamination risks and ensure compliance with storage conditions for rejected materials.
Excerpt: A red reject rectangular box labeled Sodium Chloride 0.9% was directly dripping (leaking) on a pallet with a Finished Product Inventory Log sheet placed on top.
View Details
Separate or defined areas to prevent contamination or mix-ups are deficient regarding operations related to the receipt, identification, storage, and withholding from use of components, drug product containers, and closures pending sampling, testing, or examination by the quality control unit before release for manufacturing or packaging.
Exela Pharma Sciences LLC
15 Nov 2024 Normal Justification: Material storage directly impacts product stability. Failure to ensure proper refrigeration conditions risks quality deterioration.
Excerpt: Manufacturer’s label on raw material indicates raw material API should be kept refrigerated at (b) (4).
View Details
Written procedures are lacking which describe in sufficient detail the storage of components, drug product containers and closures
Annovex Pharma, Inc.
06 Sep 2024 Normal Justification: Storage requirements are critical for material integrity. The observation indicates lapses in precisely documented procedures which are vital for 'Material Storage and Control'.
Excerpt: Written procedures are lacking which describe in sufficient detail the storage of components, drug product containers and closures.
View Details

Prepare Better for FDA Audits with FDA Tracker

Get Real-time Insights: FDA 483s & Warning letters.
Uncover Trends: FDA Investigator profiles & Observations.
Stay Compliant: Manage risks proactively.

Material Storage and Control

Explore essential insights on batch release processes to enhance compliance and quality. Dive into our article for practical guidance and best practices.

Written By
Vivek Gera
Reading Time
8
Minutes

Material Storage and Control

Overview

26
Form 483s Issued
5
483s converted to WL
28
Total Observation
Form 483s Issued
+74 from last period

Recent Form 483s & Warning Letters

Issue Date
Facility Name
Product Type
Form 483
Converted
Warning Letter
21 Feb 2025
Meds For Vets
Drugs
16 Jan 2025
Sanofi-Aventis Deutschland GmbH
Drugs
15 Nov 2024
Exela Pharma Sciences LLC
Drugs
06 Sep 2024
Annovex Pharma, Inc.
Drugs
27 Mar 2024
Alkem Laboratories Limited
Drugs

Top FDA Investigators

Investigator Name
Form 483 Count
Warning Letter Count
Lauren R Brady
2
2
Logan Williams
2
0
Joan Cantellops
2
0
Jocelyn C Turner
2
2
Margaret M Annes
2
2

Key Observations

TITLE/ COMPANY Issue Date Status Details
Use of ingredients not intended for pharmaceutical use in sterile drug production
Meds For Vets
21 Feb 2025 Normal Justification: The observation highlights the use of non-pharmaceutical grade materials, indicating a failure in material control processes.
Excerpt: The (b) (4) for irrigation used is labeled "not for injection".
View Details
01 not are used for storage, and of all during DS manufacturing
Sanofi-Aventis Deutschland GmbH
16 Jan 2025 Normal Justification: The observation highlights inadequate storage affecting product quality, emphasizing the need for stringent material control during storage.
Excerpt: storage, and of all during DS manufacturing process. Although Step utilizes a less stringent generation process.
View Details
Separate or defined areas to prevent contamination or mix-ups are deficient regarding operations related to the holding of rejected components, drug product containers, and closures before disposition.
Exela Pharma Sciences LLC
15 Nov 2024 Normal Justification: Proper material storage controls prevent contamination risks and ensure compliance with storage conditions for rejected materials.
Excerpt: A red reject rectangular box labeled Sodium Chloride 0.9% was directly dripping (leaking) on a pallet with a Finished Product Inventory Log sheet placed on top.
View Details
Separate or defined areas to prevent contamination or mix-ups are deficient regarding operations related to the receipt, identification, storage, and withholding from use of components, drug product containers, and closures pending sampling, testing, or examination by the quality control unit before release for manufacturing or packaging.
Exela Pharma Sciences LLC
15 Nov 2024 Normal Justification: Material storage directly impacts product stability. Failure to ensure proper refrigeration conditions risks quality deterioration.
Excerpt: Manufacturer’s label on raw material indicates raw material API should be kept refrigerated at (b) (4).
View Details
Written procedures are lacking which describe in sufficient detail the storage of components, drug product containers and closures
Annovex Pharma, Inc.
06 Sep 2024 Normal Justification: Storage requirements are critical for material integrity. The observation indicates lapses in precisely documented procedures which are vital for 'Material Storage and Control'.
Excerpt: Written procedures are lacking which describe in sufficient detail the storage of components, drug product containers and closures.
View Details

Frequently Asked Questions

Heading 1

Heading 2

Heading 3

Heading 4

Heading 5
Heading 6

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur.

Block quote

Ordered list

  1. Item 1
  2. Item 2
  3. Item 3

Unordered list

  • Item A
  • Item B
  • Item C

Text link

Bold text

Emphasis

Superscript

Subscript

Experience Leucine AI Powered pharma manufacturing
300+ pharma facilities worldwide use Leucine to stay compliant. Talk to one of our expert consultants at Leucine to learn how.
Related Resources

View and learn more about FDA Inspections
with our comprehensive list of resources